Pub. Date : 2016 Nov
PMID : 27544060
8 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. | alectinib | ret proto-oncogene | Homo sapiens |
| 2 | Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. | alectinib | ret proto-oncogene | Homo sapiens |
| 3 | The clinical activity of alectinib in patients with RET-rearranged NSCLC has not yet been reported. | alectinib | ret proto-oncogene | Homo sapiens |
| 4 | METHODS: We have described four patients with advanced RET-rearranged NSCLC who were treated with alectinib (600 mg twice daily [n = 3] or 900 mg twice daily [n = 1]) as part of single-patient compassionate use protocols or off-label use of the commercially available drug. | alectinib | ret proto-oncogene | Homo sapiens |
| 5 | A fourth patient who was RET TKI-naive had primary progression while receiving alectinib. | alectinib | ret proto-oncogene | Homo sapiens |
| 6 | CONCLUSIONS: Alectinib demonstrated preliminary antitumor activity in patients with advanced RET-rearranged NSCLC, most of whom had received prior RET inhibitors. | alectinib | ret proto-oncogene | Homo sapiens |
| 7 | CONCLUSIONS: Alectinib demonstrated preliminary antitumor activity in patients with advanced RET-rearranged NSCLC, most of whom had received prior RET inhibitors. | alectinib | ret proto-oncogene | Homo sapiens |
| 8 | Larger prospective studies with longer follow-up are needed to assess the efficacy of alectinib in RET-rearranged NSCLC and other RET-driven malignancies. | alectinib | ret proto-oncogene | Homo sapiens |